Adaptive Biotechnologies Corp develops diagnostic and therapeutic products based on decoding the adaptive immune system, with its FDA-authorized clonoSEQ assay central to minimal residual disease (MRD) detection in hematologic cancers. The company reported a net loss of $59.5 million in 2025, an improvement from prior years, supported by better operating efficiencies though cash flow remains negative. Growth opportunities are driven by expanding clinical adoption of MRD testing and Immune Medicine applications, while risks include reimbursement uncertainties, regulatory compliance, and intellectual property challenges. Monitoring revenue trends and reimbursement developments will be key to evaluating progress.